Evidence map›Paper›PMID 36937412›Full record

ReviewFrontiers in oncology2023

Advances in the treatment of Hodgkin lymphoma: Current and future approaches.

Fauzia Ullah, Danai Dima, Najiullah Omar, Olisaemeka Ogbue, Sairah Ahmed

Open access · goldFull text readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Frontiers in oncology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed, 1 pooled it
4.8field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 1 synthesis or guideline pooled it, 19 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Article
  5. Article
  6. Comparing the measurement properties of the EQ-5D-5 L, SF-6Dv2, QLU-C10D and FACT-8D among survivors of classical Hodgkin's lymphoma.The European journal of health economics : HEPAC : health economics in prevention and care · 2025
    Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Leukemic Stem Cells and Hematological Malignancies.International journal of molecular sciences · 2024
    Review
  12. Chimeric Antigen Receptor T Cells in Hodgkin and T-Cell Lymphomas.Hematology/oncology clinics of North America · 2023
    Review
  13. The Essential Oil fromPharmaceuticals (Basel, Switzerland) · 2023
    Article
  14. Review
  15. Cancer treatment and survivorship statistics, 2025.CA: a cancer journal for clinicians
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Fauzia UllahDepartment of Translational Hematology and Oncology Research, Cleveland Clinic Foundation, Cleveland, OH, United States.
Danai DimaDepartment of Translational Hematology and Oncology Research, Cleveland Clinic Foundation, Cleveland, OH, United States.
Najiullah OmarDepartment of Translational Hematology and Oncology Research, Cleveland Clinic Foundation, Cleveland, OH, United States.
Olisaemeka OgbueDepartment of Translational Hematology and Oncology Research, Cleveland Clinic Foundation, Cleveland, OH, United States.
Sairah AhmedDepartment of Lymphoma/Myeloma and Stem Cell Transplant & Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX, United States.
Cleveland Clinic · USThe University of Texas MD Anderson Cancer Center · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Hodgkin lymphoma (HL) is a rare type of lymphoma with unique histologic, immunophenotypic, and clinical features. It represents approximately one-tenth of lymphomas diagnosed in the United States and consists of two subtypes: classical Hodgkin's lymphoma (cHL), which accounts for majority of HL cases, and nodular lymphocyte predominant Hodgkin lymphoma represent approximately 5% of Hodgkin lymphoma cases. From this point, we will be focusing on cHL in this review. In general, it is considered a highly curable disease with first-line chemotherapy with or without the addition of radiotherapy. However, there are patients with disease that relapses or fails to respond to frontline regimens and the standard treatment modality for chemo sensitive cHL is high dose chemotherapy followed by autologous hematopoietic stem cell transplant (AHSCT). In recent years, targeted immunotherapy has revolutionized the treatment of cHL while many novel agents are being explored in addition to chimeric antigen receptor (CAR) T-cell therapy which is also being investigated in clinical trials as a potential treatment option.

Indexed as

chemoimmunotherapychimeric antigen receptor (CAR) T-cell therapyClassical Hodgkin lymphoma (cHL)hematopoietic stem cell transplantrelapsed and refractory Hodgkin's lymphoma

Identifiers

PMID36937412
PMCPMC10020509
OpenAlexW4323044933

What OpenQuestion holds

Textfull text, public
LicenceCC BY
measurements read336
identifiers read14
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.